# BioBrit

> BioBrit is a VC fund in La Jolla backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: La Jolla, United States
- Total investments: 11
- Last investment: Mar 2022
- Lead investor: 18%
- Last updated: Aug 2026
- Website: http://biobrit.com/

BioBrit is a VC fund in La Jolla focused on Biotechnology and Health Care. Founded in 2012, BioBrit is a life sciences consulting and investment firm located in La Jolla, California.

## Contacts

5 contacts available for BioBrit. Shizune tracks 1 team members at BioBrit. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biobrit-llc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 73% |
| Health Care | 4 | 36% |
| Therapeutics | 4 | 36% |
| Biopharma | 2 | 18% |
| Life Science | 2 | 18% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 45% |
| Seed | 3 | 27% |
| Funding Round | 2 | 18% |
| Series B | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 64% |
| Trinidad and Tobago | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Bradbury | Managing Member | 2 | https://shizune.co/investors/profile/daniel-m-bradbury |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Creyon Bio | Creyon Bio is a pre-clinical stage company reimagining drug development as it should be, using a data-first approach for generating uniquely powerful datasets and developing machine learning models to uncover the engineering principles that make precision oligonucleotide-based medicines possible for patient populations of all sizes. | $40M | Series A | Mar 08, 2022 |  |
| Basilard BioTech | Basilard BioTech features a technology platform that transforms the rapidly growing cell-based therapies market. Cell and Gene Therapies (CGT) have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and killmillions of people. |  | Seed | Oct 06, 2021 |  |
| Amplo Biotechnology | Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program,AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases. | $2.2M | Seed | Oct 01, 2021 |  |
| Stuart Therapeutics | Stuart Therapeutics is a biotechnology company that offers PolyCol, a therapeutic platform for ophthalmic indications.PolyCol’s unique method of action results in accelerated healing and recovery in various ophthalmic disease states and offers a new way to address indications such as dry eye disease, dry age related macular degeneration, andglaucoma.PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions. | $11M | Series A | Mar 19, 2021 |  |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $27.4M | Series A | Oct 27, 2020 |  |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $7M | Seed | Mar 02, 2020 |  |
| Castle Biosciences | Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. The company also focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions.The DecisionDx family of molecular diagnostictests have the ability to meaningfully impact how cancers are diagnosed and managed and the DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer, including the risk of sentinel lymph node positivity.Castle Biosciences was founded in 2008 and is headquartered in Friendswood, Texas, United States. | $5.1M |  | Jun 11, 2018 |  |
| Compass Therapeutics | Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. |  | Series A | Jul 11, 2017 |  |
| SiteOne Therapeutics | SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of avoltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals. | $15M | Series B | Jan 06, 2017 |  |
| SiteOne Therapeutics | SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of avoltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals. | $1.3M |  | Jul 15, 2015 |  |

10 of 11 investments shown.

## Co-investors
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 3 deals together
- Sears Capital Management — VC Fund, 3 deals together
- BioRock Ventures Name — VC Fund, 2 deals together
- [CAM Capital](https://shizune.co/investors/profile/camcapital) — VC Fund, 2 deals together
- [Mission Bay Capital](https://shizune.co/investors/profile/mission-bay-capital-llc) — VC Fund, 2 deals together
- [NEXT Frontier Capital](https://shizune.co/investors/profile/next-frontier-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does BioBrit invest in?

BioBrit invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BioBrit?

Public channels for BioBrit include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioBrit?

The team at BioBrit includes Daniel Bradbury (Managing Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co